FDA Determines Regulatory Review Period for REYVOW Patent Extension

Summary

The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for the patent extension of REYVOW, a human drug product, following a submission to the US Patent and Trademark Office (USPTO).